ALK and non-small cell lung carcinoma: The PROFILE 1014 study demonstrated that, compared with standard platinum-based chemotherapy, crizotinib significantly prolonged the median progression-free survival (mPFS, 10.9 months vs. 7.0 months; p < 0.001) and objective response rate (ORR, 74% vs. 45%; p < 0.001) of previously untreated patients with ALK-positive advanced NSCLC [13].